- Home
- DNTH vs NMM Comparison
DNTH vs NMM Comparison
Compare DNTH & NMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- NMM
- Stock Information
- Founded
- DNTH 2015
- NMM 2007
- Country
- DNTH United States
- NMM Greece
- Employees
- DNTH N/A
- NMM N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- NMM Marine Transportation
- Sector
- DNTH Health Care
- NMM Consumer Discretionary
- Exchange
- DNTH Nasdaq
- NMM Nasdaq
- Market Cap
- DNTH 1.4B
- NMM 1.3B
- IPO Year
- DNTH N/A
- NMM 2007
- Fundamental
- Price
- DNTH $33.67
- NMM $48.94
- Analyst Decision
- DNTH Strong Buy
- NMM
- Analyst Count
- DNTH 11
- NMM 0
- Target Price
- DNTH $65.22
- NMM N/A
- AVG Volume (30 Days)
- DNTH 516.1K
- NMM 93.8K
- Earning Date
- DNTH 11-07-2025
- NMM 11-04-2025
- Dividend Yield
- DNTH N/A
- NMM 0.42%
- EPS Growth
- DNTH N/A
- NMM N/A
- EPS
- DNTH N/A
- NMM 10.24
- Revenue
- DNTH $4,854,000.00
- NMM $1,305,026,000.00
- Revenue This Year
- DNTH N/A
- NMM N/A
- Revenue Next Year
- DNTH N/A
- NMM $9.93
- P/E Ratio
- DNTH N/A
- NMM $4.74
- Revenue Growth
- DNTH 17.87
- NMM N/A
- 52 Week Low
- DNTH $13.37
- NMM $28.37
- 52 Week High
- DNTH $40.16
- NMM $55.37
- Technical
- Relative Strength Index (RSI)
- DNTH 46.99
- NMM 63.06
- Support Level
- DNTH $32.28
- NMM $47.47
- Resistance Level
- DNTH $35.40
- NMM $49.33
- Average True Range (ATR)
- DNTH 1.59
- NMM 1.01
- MACD
- DNTH -0.20
- NMM 0.39
- Stochastic Oscillator
- DNTH 26.53
- NMM 92.17
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.